# Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

> **NCT04952610** · PHASE3 · COMPLETED · sponsor: **Milestone Pharmaceuticals Inc.** · enrollment: 130 (actual)

## Conditions studied

- Paroxysmal Supraventricular Tachycardia

## Interventions

- **DRUG:** Etripamil NS 70 mg
- **DEVICE:** Aptar Pharma Nasal Spray Bidose System

## Key facts

- **NCT ID:** NCT04952610
- **Lead sponsor:** Milestone Pharmaceuticals Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-04-10
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952610, "Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT04952610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*